Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement (TAVR) DUBLIN, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the ...
More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...
GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
The latest generation of Medtronic’s transcatheter aortic valve replacement implant has passed the FDA’s muster. Like those that came before it, the new Evolut FX+ is placed through a minimally ...
After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest version of its transcatheter aortic valve replacement implant. Compared to ...
DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the ...
Medtronic is pumping up its activation of heart valve disease patients. The company has partnered with an advocacy group for heart valve disease, Heart-Valve-Surgery.com, to create a digital platform ...
Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Medtronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback